Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$98.6M Buy
280,032
+463
+0.2% +$165K 0.49% 35
2025
Q4
$91.6M Buy
279,569
+34,537
+14% +$11M 0.48% 34
2025
Q3
$69M Buy
245,032
+2,027
+0.8% +$588K 0.44% 39
2025
Q2
$67.7M Buy
243,005
+37,457
+18% +$10.6M 0.52% 34
2025
Q1
$63.2M Buy
205,548
+24,845
+14% +$7.34M 0.67% 23
2024
Q4
$47.2M Buy
180,703
+91,794
+103% +$27.2M 0.57% 35
2024
Q3
$28.7M Buy
88,909
+48,030
+117% +$15.7M 0.55% 31
2024
Q2
$12.8M Buy
40,879
+31,824
+351% +$9.35M 0.56% 33
2024
Q1
$2.59M Buy
+9,055
New +$2.65M 0.36% 56
2023
Q4
Sell
-6,477
Closed -$1.74M 295
2023
Q3
$1.74M Buy
6,477
+9
+0.1% +$2.25K 0.81% 24
2023
Q2
$1.44M Hold
6,468
0.64% 29
2023
Q1
$1.56M Buy
6,468
+32
+0.5% +$7.86K 0.75% 26
2022
Q4
$1.69M Sell
6,436
-262
-4% -$70.2K 0.84% 23
2022
Q3
$1.51M Sell
6,698
-2
-0% -$485 0.87% 24
2022
Q2
$1.63M Buy
6,700
+2
+0% +$490 0.94% 20
2022
Q1
$1.62M Buy
6,698
+9
+0.1% +$2.07K 0.91% 22
2021
Q4
$1.5M Hold
6,689
0.91% 19
2021
Q3
$1.42M Hold
6,689
0.9% 25
2021
Q2
$1.63M Buy
6,689
+100
+2% +$24.6K 1.05% 18
2021
Q1
$1.64M Hold
6,589
1.19% 17
2020
Q4
$1.51M Buy
6,589
+100
+2% +$23.1K 1.27% 17
2020
Q3
$1.65M Hold
6,489
1.68% 9
2020
Q2
$1.53M Buy
+6,489
New +$1.48M 1.85% 15

Other funds holding AMGN

&Partners's AMGN Position: Q1 2026 in Review

&Partners increased its Amgen (AMGN) stake by 0.17% in Q1 2026, buying an estimated $165K and bringing the position to 280,032 shares worth $98.6M. The position accounts for 0.49% of the portfolio, ranked #35.

&Partners first reported a position in AMGN in Q2 2020 and has held it in 23 quarters since. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • &Partners held 280,032 shares of Amgen worth $98.6M as of Q1 2026.
  • &Partners bought 463 Amgen shares in Q1 2026, an estimated $165K.
  • Amgen made up 0.49% of &Partners's portfolio in Q1 2026, its #35 holding.
  • &Partners first reported a position in Amgen in Q2 2020 and has held it in 23 quarters since.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.